Sinovac Biotech Ltd (SVA) stock

SVANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026Score 6/30

$6.47+0.00 (0.00%)

Close on Nov 13, 2026Market cap $464.94MP/E –Yield 850.08%

Sinovac Biotech statistics

76 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: Jul 8, 2025
Fundamentals through: Dec 31, 2025
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $464.94M; $272.32M
Enterprise Value: -$3.55B; $146.23M
PS Ratio: 1.20; 3.66
PB Ratio: 0.10; 2.00
P/TBV Ratio: 0.11; 2.22

Enterprise valuationIndustry

EV / Sales: -9.19; 2.57

Share statisticsIndustry

Shares Outstanding: 72M; 58M
Shares Change (YoY): 0.00%; 10.8%
Float: 25M; 49M
Shares Held by Insiders: 65.7%; 11.7%
Shares Held by Institutions: 14.6%; 56.4%

Short sellingIndustry

Short Interest: 82,156; –
Short Interest Change: 0.00%; -0.80%
Short % of Float: 0.33%; 9.01%
Short % of Shares Outstanding: 0.11%; 6.30%
Days to Cover: 999.99; 5.15

Stock price statisticsIndustry

52-Week High: $6.47; –
52-Week Low: $6.47; –
20-Day Moving Average: $6.47; –
50-Day Moving Average: $6.47; –
200-Day Moving Average: $6.47; –
Average True Range (14): $0.00; –
Price Change (1 Week): 0.00%; -1.15%
Price Change (1 Month): 0.00%; -4.87%
Price Change (3 Months): 0.00%; -21.0%
Price Change (6 Months): 0.00%; -20.6%
Price Change (YTD): 0.00%; -23.6%
Price Change (1 Year): 0.00%; -22.4%
Price Change (3 Years): 0.00%; -29.5%
Price Change (5 Years): 0.00%; -77.9%
Price Change (10 Years): 6.07%; -65.4%
Relative Strength Index (14): 100.0; 43.4
Volatility (1 Year): 0.00%; 80.1%
Beta (5 Years): 0.00; 1.07

MarginsIndustry

Gross Margin: 67.9%; 53.1%
Operating Margin: -127.0%; -38.7%
Pretax Margin: -67.9%; -11.6%
EBITDA Margin: -127.0%; -27.7%
FCF Margin: -145.4%; -9.56%

Returns on capitalIndustry

Return on Capital Employed (ROCE): -7.00%; -37.9%

Financial positionIndustry

Current Ratio: 4.59; 3.30
Quick Ratio: 4.06; 2.39

GrowthIndustry

Revenue Growth (YoY): 6.82%; 6.82%
EPS Growth (YoY): -165.4%; -12.3%
Revenue Growth (3Y CAGR): -36.0%; 2.25%
Revenue Growth (5Y CAGR): -5.44%; 6.41%

EfficiencyIndustry

Asset Turnover: 0.04; 0.40
Inventory Turnover: 1.30; 2.73
Revenue Per Employee: $148.35K; $429.29K
Employee Count: 2,602; 74
WACC: 7.60%; 10.2%

Income statement (TTM)Industry

Revenue: $386.01M; $66.37M
Gross Profit: $261.98M; $120.78M
Operating Income: -$490.13M; -$21.37M
Pretax Income: -$262.10M; -$12.95M
EBITDA: -$490.13M; -$17.21M
EPS (Diluted): -$0.83; -$0.76

Balance sheetIndustry

Cash & Short-Term Investments: $5.97B; $68.68M
Net Cash (Debt): $5.97B; $17.76M
Net Cash Per Share: $83.10; $0.80
Equity (Book Value): $4.44B; $53.89M
Book Value Per Share: $61.77; $1.50
Tangible Book Value: $4.35B; $27.13M
Working Capital: $5.52B; $79.99M

Cash flow (TTM)Industry

Operating Cash Flow: -$512.18M; -$12.38M
Capital Expenditures: -$48.92M; -$1.00M
Free Cash Flow: -$561.10M; -$18.21M
FCF Per Share: -$7.81; -$0.42

Dividends and yieldsIndustry

FCF Yield: -120.7%; -9.44%
Dividend Yield: 850.1%; 1.88%
Buyback Yield: 0.00%; -0.76%
Shareholder Yield: 850.1%; 0.00%
Dividend Per Share: $55.00; $0.83
Years of Dividend Growth: 0; 0

Taxes and interestIndustry

Income Tax: -$63.27M; $73.00K

Scores and fair valueIndustry

Altman Z-Score: 1.22; 0.23

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	SVA	S&P 500	Difference	SVA per year	S&P 500 per year
1 month	0.0%	-3.0%	+3.0 pts
3 months	0.0%	-2.8%	+2.8 pts
Year to date	0.0%	+11.5%	−11.5 pts
1 year	0.0%	+13.5%	−13.5 pts
3 years	0.0%	+77.7%	−77.7 pts	0.0%	+21.1%
5 years	0.0%	+72.6%	−72.6 pts	0.0%	+11.5%
10 years	+4.9%	+308.2%	−303.3 pts	+0.5%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M SVA shares were sold short on Oct 30, 2026, up 0.0% from the previous report, or 0.33% of the shares available to trade. At recent volumes it would take 1000.0 days to buy them back.

Settlement date	Shares short	Change	Days to cover
Oct 30, 2026	82,156	0.0%	1000.0
Oct 15, 2026	82,156	0.0%	1000.0
Sep 30, 2026	82,156	0.0%	1000.0
Sep 15, 2026	82,156	0.0%	1000.0
Aug 31, 2026	82,156	0.0%	1000.0
Aug 14, 2026	82,156	0.0%	1000.0
Jul 31, 2026	82,156	0.0%	1000.0
Jul 15, 2026	82,156	0.0%	1000.0
Jun 30, 2026	82,156	0.0%	1000.0
Jun 15, 2026	82,156	-0.7%	1000.0
May 29, 2026	82,747	0.0%	1000.0
May 15, 2026	82,747	-0.0%	1000.0

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Sinovac Biotech's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SVA.

Compare: SVA vs HCM · SVA vs ZLAB · SVA vs AAPG · SVA vs NVAX · SVA vs KMDA

Revenue growth6.8% · median -2.1%

Gross margin67.9% · median 54.7%

Operating margin-127.0% · median -42.1%

Company	Revenue	Growth
ZLAB	$441.73M	+0.0%
NVAX	$411.65M	-61.3%
SVA	$386.01M	+6.8%
HCM	$204.89M	-4.3%
KMDA	$191.85M	+13.2%
AAPG	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 2,602
Held by institutions: 14.6%
Auditor: Zhonghua Certified Public Accountants LLP
SEC CIK: 1084201

Advertisement
300 × 250

See a number that looks wrong?